Today: 11 June 2026
BAT share price holds near highs as buyback filings roll in ahead of dividend, results
24 January 2026
1 min read

BAT share price holds near highs as buyback filings roll in ahead of dividend, results

London, Jan 24, 2026, 08:28 GMT — Markets have shut for the day.

  • Shares of British American Tobacco closed Friday 0.35% higher, around 4,328 pence.
  • The company carried out another round of buybacks, planning to cancel the repurchased shares.
  • Coming up: a dividend payout on Feb. 4, followed by preliminary full-year results on Feb. 12.

British American Tobacco (BATS.L) shares closed Friday up 0.35% at roughly 4,328 pence, hovering near a 52-week peak. The stock is drawing attention from income investors as the company approaches its upcoming results.

London markets are closed until Monday, leaving the immediate question: will the steady stream of buybacks and an upcoming dividend sustain the stock, or will investors begin selling ahead of the full-year results?

BAT disclosed in a Thursday filing that it purchased 161,326 shares on Jan. 21 under its buyback scheme, at a volume-weighted average price of 4,251.0001 pence each. The firm plans to cancel these shares, cutting the total number with voting rights.

The day before, BAT disclosed it bought 160,365 shares on Jan. 20 at a volume-weighted average price of 4,253.4311 pence, with plans to cancel them.

The buyback is notable as it takes place during the company’s closed period before earnings. BAT has partnered with UBS to execute the next tranche, slated for Jan. 2 through Feb. 11. The company confirmed that shares bought back under this programme will be cancelled, cutting the share capital.

BAT’s financial calendar lists its preliminary statement for 2025 on Feb. 12. Investors will be watching closely for any changes in outlook on growth, pricing, and smokeless products.

The last major update from management arrived in December, with BAT confirming its 2026 outlook and unveiling a £1.3 billion share buyback planned for that year. Chief executive Tadeu Marroco stated then: “Full-year delivery remains on track.” bat.com

The update highlighted ongoing tensions in the U.S. vaping market, where illicit products continue to pressure legal brands. Still, BAT noted “encouraging” gains in Vuse volumes and revenue. bat.com

But the setup carries risks. If the move to newer nicotine products slows, regulation tightens, or tax hikes hit major markets, sentiment could sour fast. The U.S. vapour segment facing fresh pressure would only add to the strain, particularly given how close shares are to recent peaks.

Investors will focus on the speed and pricing of buybacks in the upcoming session and throughout the week. They’ll also watch for any broad shifts in defensive, high-yield sectors. The next key cash event is the dividend payment scheduled for Feb. 4.

Next up is Feb. 12, when BAT releases its preliminary full-year results and sheds light on its 2026 delivery outlook.

Stock Market Today

  • AMD Stock Price Forecast: Analyst Lowers Target Amid AI Market Caution
    June 11, 2026, 11:00 AM EDT. Shares of Advanced Micro Devices (AMD) have surged 111% year-to-date, driven by investor optimism over its expanding role in the artificial intelligence (AI) sector. Despite the strong performance, a prominent AI-focused analyst has trimmed the price target for AMD, signaling caution about the chipmaker's near-term prospects. The analyst cited concerns over competitive pressures and potential market saturation. AMD's growth is largely tied to its ability to capture demand in AI computing, a fast-evolving field requiring specialized semiconductor technology. Investors are weighing the company's robust sales against risks from supply chain constraints and intensifying industry competition.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 24.01.2026

Fortinet stock jumps on TD Cowen upgrade — what FTNT investors watch before earnings
Next Story

Fortinet stock jumps on TD Cowen upgrade — what FTNT investors watch before earnings

Go toTop